Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells

Chu-Che Lee, Po-Yu Huang, Yi-Hsien Hsieh, Yong-Syuan Chen, Jen-Pi Tsai

Introduction
Renal cell carcinoma (RCC), which accounting for most of the new cases of kidney cancer, increased in incidence by 2.4% per year and with a limited median survival time and overall survival when metastasis [1,2]. Therapies to treat RCC including surgery and immunotherapy, but the efficacy was limited when RCC was diagnosed with distant metastasis [3]. Recently, inhibitors of tyrosine kinase and mTOR inhibitors to target against RCC had led to better survival but the outcome of advanced stage or distant metastasis of RCC remained to be improved [4].

Of these novel target therapies, sorafenib, which had been known as a multi-kinase inhibitor with anti-angiogenic and proapoptotic activities to improve the outcomes in hepatocellular carcinoma patients [5], and had been demonstrated to be effective against multiple cancer cells through inducing apoptosis in bladder cancer cells [6], synergistically with benofuroxann derivative in lung carcinoma [7], and with fusariotoxin enniatin B in cervical cancer [8]. In addition, sorafenib was proved to be effective in treating advanced RCC with improvement of progression-free survival (< 0.002), tumor grade (< 0.001) and tumor stage (< 0.001) in human RCC.

Conclusion: Our results demonstrated that concomitantly used melatonin and sorafenib could significantly reduce the abilities of migration and invasion of RCC cells through inhibiting MTA2 expression. Therefore, our results suggested that cotreatment with melatonin and sorafenib significantly reduced migration and invasion in human RCC cells and HK2 cells. Additionally, cotreatment with melatonin and sorafenib synergistically reduced migration and invasion in human Caki-1 and ACHN cells through synergistically suppression of MTA2 expression. Bioinformatics analysis showed that MTA2 expression significantly correlated with overall survival (< 0.002), tumor grade (P < 0.001) and tumor stage (P < 0.001) in human RCC.

Keywords: Metastasis-associated protein 2, Renal cell carcinoma, Sorafenib

Abstract
Objectives: Renal cell carcinoma (RCC) was the most common and lethal urological malignancy with the dismal outcome when distant metastasis. Melatonin was known as a potential oncostatic agent against several types of malignancy and sorafenib had been considered as an agent to treat RCC, but the synergistic effects of melatonin and sorafenib on human RCC have not been elucidated. Materials and Methods: Human renal cancer cell lines (Caki-1 and ACHN) were treated with melatonin combined with sorafenib were detected the cell growth and cell cycle by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay and flow cytometry. The ability of cell migration/invasion was performed with in vitro migration and invasion assay. The proteins and mRNA expression of metastasis-associated protein 2 (MTA2) from the RCC cells were measured by quantitative reverse transcription-polymerase chain reaction and western blotting. Clinical significance of MTA2 in RCC tissues was analyzed from The Cancer Genome Atlas database by using TISIDB software. Results: Our results showed that melatonin combined with sorafenib, sorafenib or melatonin-treated alone did not induce the cytotoxic effects or cell cycle arrest in human RCC cells and HK2 cells. Additionally, cotreatment with melatonin and sorafenib synergistically reduced migration and invasion in human Caki-1 and ACHN cells through synergistically suppression of MTA2 expression. Bioinformatics analysis showed that MTA2 expression significantly correlated with overall survival (< 0.002), tumor grade (P < 0.001) and tumor stage (P < 0.001) in human RCC.

Conclusion: Our results demonstrated that concomitantly used melatonin and sorafenib could significantly reduce the abilities of migration and invasion of RCC cells through inhibiting MTA2. We considered that this novel promising combination strategy towards the treatment of RCC, but further studies are warranted.

Keywords: Melatonin, Metastasis-associated protein 2, Renal cell carcinoma, Sorafenib

Address for correspondence: Dr. Jen-Pi Tsai, Division of Nephrology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 2, Min-Sheng Road, Dalin, Chiayi, Taiwan.
E-mail: tsaininimd41491@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Lee CC, Huang PY, Hsieh YH, Chen YS, Tsai JP. Melatonin combined with sorafenib synergistically inhibit the invasive ability through targeting metastasis-associated protein 2 expression in human renal cancer cells. Tzu Chi Med J 2022;34(2):192-9.
survival [9] and showed comparable therapeutic efficacy to other target therapies in advanced RCC [10,11]. When treating RCC, sorafenib could being synergistically used with other agents, such as vascular endothelial growth factor inhibitor, to improve survival and quality of life of patients [12].

Mounting evidence had demonstrated that melatonin (N-acetyl-5-methoxytryptamine), a molecule with diverse functions including antioxidant, and-inflammation, pro-apoptosis and even anti-invasion and anti-migration [13], having beneficial application in the treatment of a myriad of tumors, including nasopharyngeal carcinoma, osteosarcoma, cervical cancer and RCC [14-17]. Furthermore, co-treatment with melatonin could enhance the abilities of other chemotherapeutic agents, including sorafenib, to suppress the carcinogenesis of hepatocellular carcinoma, pancreatic cancer, and acute myeloid leukemia through mediating the generation of reactive oxygen species (ROS), whose accumulation could lead to apoptosis [18-21].

As distant metastasis required dysregulation of cytoskeleton and cell-environment interactions to disseminate from the primary origin to distant sites and metastasis-associated protein 2 (MTA2), being a member of the metastasis tumor-associated family of transcriptional regulators, was known to play an important role in the process of tumorigenesis including distant metastasis [22-25]. Evidence had shown that overexpression of MTA2 was related to increased abilities of tumor invasion, metastasis, and poor prognosis in multiple human cancers [23-26]. We recently found that increased expression of MTA2 was associated with RCC grade and independently predicted poor overall survival; while the abilities of migration, invasion, and metastasis decreased markedly of RCC cells after downregulation of MTA2 [27].

Taken these studies together, it had been shown that individual use of melatonin and sorafenib alone could retard the progression of RCC and that concomitant use could inhibit several kinds of cancers, but to the best of our knowledge, the effects of concomitant use of melatonin and sorafenib on the tumorigenesis of RCC remained unclear. Therefore, we investigate the mechanisms of melatonin and sorafenib on the tumorigenesis as well as the role of modulating the expression of MTA2 of RCC cells.

**Materials and methods**

**Chemical reagents and antibody**

Melatonin (Product Number: 461326; purify ≥98%), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) (Product Number: M2128), dimethyl sulfoxide (DMSO, Product Number: D2650) and propidium iodide (PI) (Product Number: P4170) were purchased from Sigma (St. Louis, MO, USA). Sorafenib (BAY 43-9006) was purchased from Selleck Chemicals LLC (Houston, USA) and dissolved in DMSO solution at final concentration at 100 mM. Melatonin was dissolved in ddH2O at stock concentration of 1 M and sorafenib was dissolved in DMSO solution and stored at −20°C. Specific primary antibodies against MTA2 (sc-55566), -actin (sc-69879), and second antibodies against goat anti-mouse IgG-HRP (sc-2302) and goat anti-rabbit IgG-HRP (sc-2357) antibodies were obtained from Santa Cruz Biotecnology (Santa Cruz, CA, USA).

**Cell culture**

Human renal cancer cells lines Caki-1 and ACHN were purchased from the American Type Culture Collection (ATCC, Manassas, USA). Both RCC cells were cultured in MEM medium. Normal proximal tubular HK2 cells were cultured in DMEM-F12 medium supplemented with 10% fetal bovine serum (FBS) (HyClone, USA) and 1% penicillin/ streptomycin followed by humidified atmosphere containing 5% CO2 at 37°C. The cell culture passages number of Caki-1 was below 30, whereas for the ACHN cells not more than 40 passages number was used. Each cell culture passage was duplicate in further experiment.

**Cell viability assessment**

HK2 and RCC cells were treated with melatonin (4 mM), sorafenib (2.5 and 5 μM) or a combination of both drugs for 24 h by using the MTT assay. After treatment for 24 h, culture medium was removed and then cells were added with 0.5 mg/mL MTT for 4 h. Then isopropanol was added to dissolved the blue formazan crystals and was detected at 570 nm using an enzyme-linked immunosorbet assay plate reader.

**Propidium iodide staining by flow cytometry analysis**

Cell cycle assay was performed as described in a previous report [28]. RCC cell (5 × 10⁴/well) were added with melatonin (4 mM), sorafenib (2.5 and 5 μM) or a combination of both drug for 24 h were detected with PI staining by flow cytometry, then fixed with 70% ice ethanol for 2 days. These fixed cells were stained with PI reagent for 20 min. Cell DNA content was measured through flow cytometry by using the Muse Cell Analyzer (Merck Millipore, Burlington, MA, USA).

**In vitro migration and invasion assay**

Using a 24-well modified Boyden chamber containing the 8-μm pore size of the membrane (Millipore) were determined with cell migrated ability by cell migration assay. Precoated 5% Matrigel matrix on membrane filter inserts for cell invasion assay. RCC cells (4 × 10³/well) are seeded in the top of the insert in MEM medium (serum free), while medium containing 10% FBS are placed in the 24-well below and incubated for 16 h. The migrate cells were determined by using a microscope at × 200. The fourth fields were counted for each filter, and each sample was assayed in triplicate.

**Western blotting**

Cells were washed with phosphate-buffered saline and resuspended in lysis reagent with 1% NP40 and proteinase phosphatase inhibitor cocktails (Roche Molecular Biochemicals). Then quantified the protein concentration was detected using the Bradford method. Total proteins (20 μg) were separated using 10%–12% sodium dodecyl-sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membrane. Membranes incubated with 5% nonfat milk buffer (20 mM Tris-HCl, pH 7.6, 150 mM NaCl, and 0.1% Tween 20) for 1 h. Then, PVDF membranes were incubated with MTA2 and -actin antibodies at 4°C overnight. Next days washed the membrane for twice and incubated with horseradish peroxidase-linked
anti-mouse or anti-rabbit antibodies. Antibody-bound protein bands were detected using highly sensitive Immunoblot Western Chemiluminescent HRP Substrate (Millipore, Billerica, MA, USA), and photographed with an LAS-4000 mini luminescent image analyzer.

Quantitative reverse transcription-polymerase chain reaction analysis

Total RNA was isolated using TRIzol reagents (Invitrogen, USA), and 0.5 μg RNA was used to synthesize cDNA with a GoScript™ Reverse Transcription Mix, Oligo (dt) (A2791, Promega, Wisconsin, USA). cDNA was performed with a GoTaq® Green Master Mix (M7122 Promega, Wisconsin, USA). Primer sequences for MTA2: Forward, 5'-GTTCCTGGCAATACCGCGAGT-3' and reverse, 5'-CTTCGGGCTGAATGCACAAAAG-3'. GAPDH: Forward, 5'-CATCATCCCTGCCTCTACTG-3' and reverse, 5'-GCCTGCTTCACCACCTTC-3'. GAPDH served as an internal control. All quantitative reverse transcription-polymerase chain reaction (qRT-PCR) reactions were run in triplicate and normalised by the internal control products of GAPDH and 2-ΔCT method was used to calculate the relative expression levels.

Bioinformatic databases

The TISIDB (http://cis.hku.hk/TISIDB), an online database containing RNA expression information, tumor stage, tumor grade and overall survival data from the The Cancer Genome Atlas (TCGA) database were used for analysis and assessment of expression of MTA2 of human RCC patients.

Statistical analysis

Each experiment was repeated at least three times. Results are presented as the mean ± standard error. Statistical analyses and comparisons were made using GraphPad Prism 4 (GraphPad Software Inc. San Diego, CA, USA) and SPSS (version 18.0). Significance was defined at the *P < 0.05 or 0.01 levels.

RESULTS

Effect of melatonin combined with sorafenib on cell growth in human Renal cell carcinoma cells and in normal HK2 cells

The chemical structure of melatonin and sorafenib is shown in Figure 1a. In this study, using the concentration of melatonin and sorafenib as previously reports [29,30]. To test the potential antitumor effect of melatonin combined with sorafenib on human two RCC cell lines Caki-1, ACHN, normal proximal tubule epithelial cell lines HK2. Treatment with melatonin (4 mM) or melatonin (4 mM) combined with sorafenib (2.5 and 5 μM) for 24 h we showed that melatonin (4 mM), or melatonin (4 mM) combined with sorafenib (2.5 and 5 μM) were not affect cell growth rates of human HK2 cells [Figure 1b]. Likewise, not affect the cell growth of both Caki-1 and ACHN cells in these combine treatment [Figure 1c and d]. The IC50 value of melatonin and sorafenib treated in Caki-1 cells with an IC50 of 6.23 ± 1.2 mM and 7.62 ± 2.5 μM at 24 h; ACHN cells with an IC50 of 6.84 ± 1.5 mM and 8.59 ± 3.1 μM at 24 h. Based on these observations, melatonin combined with sorafenib at these concentrations did not exhibit significant cytotoxicity.

Melatonin combined with sorafenib not induce cell cycle arrest of human RCC cells

To examine the effect of melatonin combined with sorafenib on the human RCC cell cycle were detected with PI staining by flow cytometry. As shown in Figure 2, our results showed that treated only with melatonin (4 mM) in RCC cells, the cell cycle phase were not significantly changed. Similar results in melatonin (4 mM) combined with sorafenib (2.5 and 5 μM) for 24 h was detected with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. These data are presented as the mean ± standard deviation of three independent experiments.

Metastasis-associated protein 2 expression was required for migration/invasion inhibition by melatonin combined with sorafenib, and high expression of metastasis-associated protein 2 is closely associated with poor prognosis of renal cell carcinoma

Previous studies have shown that MTA2 involved in RCC cell migration and invasion [27]. Our results found that downregulation of MTA2 in melatonin-treated RCC cells, cotreatment of melatonin (4 mM) and sorafenib...
(2.5 or 5 μM) significantly inhibited the protein [Figure 4a, left panel: Caki-1; right panel: ACHN] and mRNA [Figure 4b, left panel: Caki-1; right panel: ACHN] expression of MTA2 by using western blotting and qRT-PCR assay. Next, we examined the expression of MTA2 in RCC tumor tissues from TCGA database using TISIDB software. Moreover, the MTA2 expression was significantly higher in the high risk group of RCC tissues and increased with increasing tumor grade [Figure 4c, R = 0.173, P = 6.5 × 10⁻⁵] and tumor stage [Figure 4d, R = 0.161, P = 0.000198] according to the analysis results from the TISIDB software. To further clarify whether MTA2 expression was correlated with the overall survival of patients with RCC by using Kaplan–Meier survival analyses, to find that high MTA2 expression in RCC patients had a significantly lower survival rate compared with low MTA2 expression in RCC patients [P < 0.001, Figure 4e].

These results demonstrated that MTA2 could be a prognostic marker for RCC patients and it’s involved in regulation of RCC cell metastasis.

**DISCUSSION**

In this study, we found that (1) enhanced expression of MTA2 was correlated with higher grade and poor survival of RCC patients; (2) melatonin alone or concomitant with sorafenib could inhibit RCC cells’ invasive and migratory abilities with no cytotoxicity of RCC; (3) concomitant treatment of RCC with melatonin and sorafenib could inhibit the protein and mRNA expression of MTA2, which indicated poor prognosis when highly expressed of human RCC [Figure 5].

Over the past decades, the incidence of kidney cancer had increased steadily over the world due to improved imaging
techniques, but the outcome was dismal when there was distant metastasis \[31,32\]. Recently, in addition to those traditional treatments including surgical and chemotherapy, regimen to treat metastatic RCC had included agents as sorafenib, sunitinib, and temsirolimus to target the signaling pathways of carcinogenesis of RCC \[33\]. As a novel cancer progression-related protein, MTA2 had been proved to inactivate p53 that leads to growth arrest and apoptosis of cancer cells \[34\] and linked with poor prognosis of several types of cancers \[24-26,35\]. Over-expression of MTA2 had been independently portended tumor invasion, metastasis, and poorer long-term survival in patients with esophageal squamous cells carcinoma \[35\]. Moreover, the expression of MTA2 was positively correlated with tumor invasion, lymph nodes metastasis in gastric cancer \[24\], which indicated its role of up-regulation to modulate the process of carcinogenesis. As the expression of MTA2 down-regulated, the abilities of invasion and migration of multiple cancers, including colorectal cancer \[23\], gastric cancer \[24\], lung cancer \[25\], and breast cancer \[26\] could be inhibited. Recently, we found that higher expression of MTA2 could mediate the expression of matrix metalloproteinase-9 (MMP-9) and was an independent prognostic factor for overall survival in RCC \[27\], which indicated that MTA2 over-expression could be a marker indicative of worse prognosis.

Sorafenib, an oral multi-tyrosine kinase inhibitor, which could affect the downstream activation of multiple signaling pathways, had been approved for the treatment of several types of cancers, including hepatocellular carcinoma, bladder cancer, and advanced RCC \[5,6,36,37\]. In addition, sorafenib was reported to decrease the viability of RCC cells by causing apoptotic cell death by activating transcription factor 4 pathways through the CCAAT/enhancer-binding
protein-homologous protein and p53 upregulated modulator of apoptosis [38]. Moreover, co-treatment of sorafenib with perifosine, an Akt and a PI3K inhibitor, or metformin could individually increase the chemosensitivity of sorafenib to induce apoptosis and inhibit the metastatic abilities of bladder cancer or hepatocellular carcinoma [6,39]. Combined treatment of benzofuroxan derivative and sorafenib showed stronger cytotoxicity and induced apoptosis [7]. We previously found that combination treatment with fisetin and sorafenib could exert greater cytotoxicity in cervical cancer through activating apoptosis with the results of decreasing tumor growth through the ERK signaling pathway than either agent used alone [40]. Taken together, we knew that sorafenib alone or in combination with other agents could enhance the effects of cytotoxicity against a myriad of cancer cells.

From the literature, in addition to its physiological roles as synchronizing circadian rhythms, antioxidant, and inflammation [13], melatonin had been known to protect against cancer by several processes, including enhancing the effects of chemotherapeutic agents by modulating the expression and phosphorylation of their targets or regulating cell death associated mechanisms such as apoptosis or autophagy [41,42]. There were studies showing the inhibitory abilities of melatonin on tumor growth and metastasis [14-17]. Melatonin could sensitize cisplatin, a kind of chemotherapy agent to induce caspase-9 dependent mitochondrial apoptosis through the JNK/Parkin/mitophagy pathway to treat cervical cancer [16]. By inhibiting CC motif chemokine ligand 24 gene expression, melatonin was demonstrated to suppress the abilities of invasion and migration via inhibiting the JNK pathway of osteosarcoma cells [15]. Of nasopharyngeal carcinoma, melatonin could inhibit metastasis by modulating the expression of MMP-9 through the transcription factor specificity protein-1 and the JNK/MAPK signaling pathway [14]. Furthermore, melatonin was shown to suppress the ability of motility of RCC by down-regulating expression of MMP-9 [17], which indicated its role to counteract tumor metastasis through modulating the remodeling of extracellular matrix. In this study, we similarly found that melatonin alone could inhibit the abilities of invasion and migration as well as the expression of MTA2 of RCC cells. To examine the role of MTA2 in the presence with melatonin and sorafenib-treated RCC cells, using the transfection of MTA2 plasmid in melatonin combined with sorafenib-treated RCC cells and clarify the metastatic role and molecular mechanism is need to further investigation.

Evidence had shown that the combination of melatonin with other agents such as thapsigargin or Kahweol could enhance the process of apoptosis of RCC cells through upregulation of CCAATenhancer-binding protein homologous protein expression or p53-upregulated modulator of apoptosis [43,44]. Furthermore, melatonin could augment the sorafenib-induced cytotoxicity as apoptosis and increased expression of ROS along with mitochondrial membrane depolarization of hepatocellular carcinoma [19,20]. Of pancreatic adenocarcinoma and acute myeloid leukemia, co-treatment of melatonin and sorafenib could synergistically induce apoptosis or enhance the accumulation of mitochondrial-mediated ROS with the results of enhancing oxidative stress and ultimately cancer cell death [18,21]. Take these studies together, it showed that co-treatment with melatonin and other chemotherapeutic agents including sorafenib could suppress the process of carcinogenesis. In this study, we additionally demonstrated that combined treatments of melatonin and sorafenib could markedly augment the inhibition of metastasis potential as well as the expression of MTA2 of RCC, which indicated concomitant use of melatonin and sorafenib could serve as a potential chemotherapeutic strategy to improve the clinical outcomes of RCC. Therefore, other important key molecules for melatonin combined with sorafenib regulate the transcription of MTA2 in RCC cell migration and invasion, which will be a focus in detailing the molecular mechanism and requires further investigation.

Metastatic RCC remained as an incurable disease in the vast majority of patients and given that the biology of RCC is complex with the results of multiple treatment decisions based on the many mechanisms that regulated tumor-cell metabolism, cell-cycle or immunological environments and that systemic therapies for advanced RCC were associated with a variety of toxicities, such as sorafenib with nephrotoxicity presented as hypertension, proteinuria or acute interstitial nephritis, novel strategy with the combination of immunomodulatory agents was considered due to favorable toxicity and durable responses [43,44]. In this study, although we demonstrated that melatonin and sorafenib could synergistically inhibit the metastasis potential of RCC through down-regulated MTA2 expression, the detailed signaling pathways to regulate the expression of MTA2 as well as the targets MTA2 acted on needed to be elucidated in future. Moreover, in vivo study should be conducted to demonstrate the beneficial synergistic effects of melatonin and sorafenib on RCC.

**Conclusion**

Taken together, our study indicated that a combination of melatonin and sorafenib exert better promising synergistic effects than either agent used alone against RCC, and this synergism is based on inhibiting the expression of MTA2. Thus, combined treatment with melatonin and sorafenib represents a novel therapeutic strategy for further clinical developments in RCC.

**Financial support and sponsorship**

This study is supported by the Ministry of Science and Technology (MOST 106-2320-B-303-003) and Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (DTCRD109(2)-E-13).

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Luzzago S, Deuker M, et al. Contemporary age-adjusted incidence and mortality rates of renal cell carcinoma: Analysis according to gender, race, stage, grade, and histology. Eur Urol Focus 2021;7:644-52.

2. Ssaad AM, Gad MM, Al-Husseini MJ, Rubhan IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United


States in the last 2 decades: A SEER-based study. Clin Genitourin Cancer 2019;17:46-57.e5.

3. Volpe A, Cadeddu JA, Cestari A, Gill JS, Jewett MA, Joniau S, et al. Contemporary management of small renal masses. Eur Urol 2011;60:501-15.

4. Chiong E, Tay MH, Tan MH, Kumar S, Sim HG, Teh BT, et al. Management of kidney cancer in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol 2012;13:e482-91.

5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.

6. Amantini C, Morelli MB, Santoni M, Soriani A, Cardinali C, Farfariello V, et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience 2015;2:395-409.

7. Teixeira SF, Alexandre de Azevedo R, Salomon MA, Jorge SD, Levy D, Bydlowski SP, et al. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomed Pharmacother 2014;68:1015-22.

8. Dornetshuber-Fleiss R, Heilos D, Mohr T, Richter L, Süssmuth RD, Teixeira SF, Alexandre de Azevedo R, Salomon MA, Jorge SD, Levy D, Bydlowski SP, et al. Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells. Biomed Pharmacother 2014;68:1015-22.

9. Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur J Cancer 2007;43:1684-92.

10. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

11. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

12. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

13. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

14. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

15. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

16. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

17. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

18. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

19. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.

20. Huang HF, Fan XR, Ji ZG. The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: A meta-analysis. Pathol Oncol Res 2019;25:1489-503.
anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signal 2009;5:117-25.

38. Wang Q, Wu G, Che X, Li Q, Zhang Z, Tang Q. Sorafenib induces renal cell carcinoma apoptosis via upregulating activating transcription factor 4. Pharmazie 2018;73:156-60.

39. Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression. Amino Acids 2014;46:2809-22.

40. Lin MT, Lin CL, Lin TY, Cheng CW, Yang SF, Lin CL, et al. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Tumour Biol 2016;37:6987-96.

41. Reiter RJ. Mechanisms of cancer inhibition by melatonin. J Pineal Res 2004;37:213-4.

42. Wang Y, Wang P, Zheng X, Du X. Therapeutic strategies of melatonin in cancer patients: A systematic review and meta-analysis. Onco Targets Ther 2018;11:7895-908.

43. Min KJ, Kim HS, Park EJ, Kwon TK. Melatonin enhances thapsigargin-induced apoptosis through reactive oxygen species-mediated upregulation of CCAAT-enhancer-binding protein homologous protein in human renal cancer cells. J Pineal Res 2012;53:99-106.

44. Um HJ, Park JW, Kwon TK. Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA. J Pineal Res 2011;50:359-66.